Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rheumatology].

H U Scherer1, G R Burmester

  • 1Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Charité - Universitätsmedizin Berlin, Germany. TUulrich.scherer@charite.deUT

Der Internist
|July 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease activity and anti-topoisomerase I antibody positivity are associated with elevated serum B cell-activating factor levels and a B cell subset-wide reduction of BAFF receptor expression in systemic sclerosis.

Rheumatology (Oxford, England)·2026
Same author

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Nature communications·2025
Same author

Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization tests.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2023
Same author

The MCP2 and the wrist plus two extensor compartments are the most affected and responsive joints/tendons out of the US7 score in patients with rheumatoid arthritis-an observational study.

Arthritis research & therapy·2022
Same author

Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFα therapy.

Arthritis research & therapy·2022
Same author

Pregnancy outcome in women with different rheumatic diseases: a retrospective analysis.

Scandinavian journal of rheumatology·2021
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Monoclonal antibodies have transformed rheumatic disease treatment, offering high response rates and reduced inflammation. However, safety and cost are key considerations for widespread patient access and evolving clinical guidelines.

Area of Science:

  • Rheumatology
  • Immunology

Context:

  • Biologic agents, particularly monoclonal antibodies, represent a significant advancement in treating rheumatic diseases.
  • Historically, achieving high response rates (>70%) with substantial reductions in inflammatory activity and radiologic progression was unattainable.

Purpose:

  • To provide an overview of current biologic agents used in rheumatology.
  • To discuss the safety and cost implications of these novel therapies.
  • To offer a perspective on future biologic agents in rheumatology.

Summary:

  • Monoclonal antibodies have revolutionized rheumatic disease treatment, demonstrating remarkable efficacy.
  • Challenges include managing safety profiles and healthcare costs associated with these advanced therapies.
  • Standardized outcome measures and updated institutional guidelines are crucial for optimal patient care.

Related Experiment Videos

Impact:

  • These advancements offer improved therapeutic options for patients with rheumatic conditions.
  • Addressing safety and cost concerns is vital for equitable access to innovative treatments.
  • The continuous evolution of biologic therapies promises further improvements in managing rheumatic diseases.